Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor - Top-Institutions - MDSpire

Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor

  • By

  • Huifang Du

  • Yifeng Zheng

  • Chentao Zhu

  • Yang Guo

  • Pengfei Li

  • Peng Hong

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Children's Oncology Group
    Children's Oncology Group

    Boulder, CO

    Key Differentiators

    • Pediatrics
    • Oncology

  • #2

    International Society of Pediatric Oncology
    International Society of Pediatric Oncology

    Bologna, Italy

    Key Differentiators

    • Pediatrics
    • Oncology

  • #3

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatrics
    • Oncology

Original Source(s)

Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor

  • by Huifang Du, Yifeng Zheng, Chentao Zhu, Yang Guo, Pengfei Li, Peng Hong

  • May 25, 2026

Related Content

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Synthetic short RNA in cancer

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma